Scholarlink

<p>Current methods for post-treatment cancer surveillance and recurrence monitoring rely mainly on biophysical imaging methods like CT and MRI. Limitations associated with these approaches include risk of radiation, high cost and sophistication in operation. Minimally invasive blood test is a very attractive alternative but there is no biomarker that is of sufficient sensitivity for this purpose. In this study, we attempted to discover novel breast cancer-associated blood plasma proteins that can fill this gap. We tested the hypothesis that genes that are co-amplified HER2 can be used as a surrogate biomarker for detection of HER2+ breast cancer. Following identification of HER2-coamplified genes via copy number variation analysis, a series of bioinformatic tools were used that eventually led to the identification of WFIKKN2 as a novel cancer-associated blood plasma protein. ELISA analysis of more than 120 plasma samples from non-cancer and cancer patients with HER2+ breast cancer revealed WFIKKN2 to have sensitivity and specificity of up to 89% and 60%, respectively. While not ideal as a diagnostic biomarker due to its moderate specificity, the high sensitivity of WFIKKN2 is suitable for the purpose of post-treatment surveillance and recurrence monitoring. The data warrants WFIKKN2 to be further evaluated through clinical studies to validate its clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

WFIKKN2 is secreted and elevated in blood plasma of HER2-positive breast cancer patients – implications in cancer surveillance and recurrence monitoring

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月5日

查看全文
  • Amir Sabbaghian,
  • Fei Xie,
  • Xiao Fang Wang,
  • Zhen Yang,
  • Ming Chen Zhang,
  • Ting Gang Chew,
  • Shu Wang,
  • Yoon Pin Lim

摘要

Current methods for post-treatment cancer surveillance and recurrence monitoring rely mainly on biophysical imaging methods like CT and MRI. Limitations associated with these approaches include risk of radiation, high cost and sophistication in operation. Minimally invasive blood test is a very attractive alternative but there is no biomarker that is of sufficient sensitivity for this purpose. In this study, we attempted to discover novel breast cancer-associated blood plasma proteins that can fill this gap. We tested the hypothesis that genes that are co-amplified HER2 can be used as a surrogate biomarker for detection of HER2+ breast cancer. Following identification of HER2-coamplified genes via copy number variation analysis, a series of bioinformatic tools were used that eventually led to the identification of WFIKKN2 as a novel cancer-associated blood plasma protein. ELISA analysis of more than 120 plasma samples from non-cancer and cancer patients with HER2+ breast cancer revealed WFIKKN2 to have sensitivity and specificity of up to 89% and 60%, respectively. While not ideal as a diagnostic biomarker due to its moderate specificity, the high sensitivity of WFIKKN2 is suitable for the purpose of post-treatment surveillance and recurrence monitoring. The data warrants WFIKKN2 to be further evaluated through clinical studies to validate its clinical utility.